Dull's posting about T-DM1 is a pathetic effort to distort. Point in fact: this article appeared in USA today almost ONE YEAR AGO (on 6/4/2012) and must, therefore, be totally discounted as to the impact T-DM1 may or may not have upon NeuVax. Furthermore, here's an essential quote the Dull Fool specifically left out from the article:
"People should be cautious about overestimating T-DM1's survival advantage, because, statistically, it's possible that those findings could be due to chance, Horning says. As researchers continue to monitor the women's progress, doctors will get a better sense if T-DM1 really improves survival."
In other words, while T-DM1 is undergoing extensive research, there was no indication as of June of last year that T-DM1 was anything more than yet another research effort under extensive review and testing. Dan
T-DM1 is designed to help prolong the life of women in their "late-stage" battle with HER2. Absolutely taking NOTHING away from these efforts, and with full empathy for those suffering, T-DM1 does NOT compete with NeuVax in any sense or in any form. I suggest we try to remain respectful of the fact that we're not here to discuss "betting odds" in Vegas or in Atlantic City. We're talking about life and quality of life and of trying to survive once diagnosed with cancer. There are no reasons, none whatsoever, in trying to offset the NeuVax potential with the advances of T-DM1. The two therapies reside in two different universes. May they BOTH succeed!!! They are NOT mutually exclusive of one another. Here is more data and as is always the case, a simple search through the literature will help everyone to fully understand not only the validity of my statements, but of T-DM1 as it continues its process and why this science does NOT conflict with the NeuVax process.
"Genentech has submitted a Biologics License Application (BLA) for trastuzumab emtansine to the U.S. Food and Drug Administration (FDA) for use in people with HER2-positive, unresectable locally advanced or metastatic breast cancer who have received prior treatment with Herceptin and a taxane chemotherapy. Roche has submitted a Marketing Authorization Application to the European Medicines Agency (EMA) for the same indication. "